A new finding by the Mesulam Center confirms primary progressive aphasia’s (PPA) unique pathologic signature, which is a critical step to eventually discovering a treatment for PPA. Tamar Gefen, PhD, is the lead author on a new publication in the Journal of Neuropathology & Experimental Neurology.
Gefen noted a discovery like this is only possible because of commitment of the Center’s research participants. “Kudos to our research participants; they are doing everything in their power to understand the disease, and to help others. They are selflessly committing themselves to years and years of evaluations so that this research can be possible.”